Research

© Cello Armstrong - Fotolia.com

Research groups

Prof. Langer
© dziemba

Prof. Dr. Klaus Langer

Research group

Focus area of research:

  • Drug targeting - nanotechnology, e.g. albumin- or PLGA based
  • Drug targeting: surface modifications
  • Tumor targeting
  • Drug formulation

  • Projects

    • Entwicklung einer Arzneiform zur TG-1-Enzymsubstitution der lamallären Ichthyose ( – )
      Individual project: United for Fighting Ichthyosis - Amici per la Pelle
    • Stabilisierung von nanopartikulären pharmazeutischen Wirkstoffen durch humanes Serumalbumin (HSA) ( – )
      Individual project: INVITE GmbH
    • PharMSchool ( – )
      Individual project: Universitätsgesellschaft Münster e.V., Deutsche Pharmazeutische Gesellschaft e.V., Rottendorf Stiftung
    • Self Immolative Drug Delivery Systems based on Polycarbonate Copolymers ( – )
      Individual project: DFG - Individual Grants Programme | Project Number: LA 1165/5-1
    • Transglutaminase 1-Liposomen - Forschungsarbeiten auf dem Gebiet der lamellären Ichthyose ( – )
      Individual project: Leibniz-Forschungsinstitut für Molekulare Pharmakologie
    • Patientenrelevanz generischer Substitution am Beispiel von L-Dopa ( – )
      Individual project: Apothekerstiftung Westfalen-Lippe | Project Number: Wa/mie
    • EXC 1003 B1 - Formation and Properties of Epithelial and Endothelial Barriers ( – )
      Subproject in DFG-joint project hosted at University of Münster: DFG - Cluster of Excellence | Project Number: EXC1003/1
    • Auftragsanalytik (REM, DSC, ...) für den Bereich der Arzneimittelherstellung ( – )
      Individual project: Rottendorf Pharma GmbH
    • Verbundprojekt: Zielgesteuerte BioTransporter oral applizierter Photosensibilisatoren zur photodynamischen Therapie gastrointestinaler Carcinome (GITCare) - Teilvorhaben: Nanostrukturierte Trägersysteme und deren biologische Bewertung ( – )
      Participation in BMBF-joint project: Federal Ministry of Education and Research | Project Number: 13N13423
    • Rezepturfit - Validierung von Rezepturprozessen ( – )
      Individual project: Apothekerstiftung Westfalen-Lippe
    • PharMSchool-Symposium ( – )
      Scientific Event: Sonstige Mittelgeber
    • BioTraP for CCC – Biokonjugate zur peroralen Anwendung für den Transport von Problemarzneistoffen zur Behandlung des Cholangiozellulären Karzinoms ( – )
      Participation in BMBF-joint project: Federal Ministry of Education and Research | Project Number: 13N11390
    • Development for nanoparticles for Parkinson disease ( – )
      Individual project: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    • NanoGene – Stem cell generation and manipulation by nanoparticle mediated gene transfer for the safe clinical application of gene-modified cells ( – )
      Participation in BMBF-joint project: Federal Ministry of Education and Research | Project Number: 13N1I539
    • NanoBrain – ERA-NET Neuron NanoBrain ( – )
      Individual project: Sonstige Mittelgeber
    • Schaltbare Nanopartikel als Wirkstoffträger ( – )
      Own resources project
    • NanoCancer – Development of cell type specific drug carrier systems for cancer therapy ( – )
      Own resources project
    • NanoDrug – Nanoparticulate dosage forms for specific tumor therapy ( – )
      Own resources project

  • Analytics / Processes

    Analytics

    • Chromatography (HPLC, GPC, FFFF)
    • Spektroscopic methods (UV, PCS; NMR, MS in cooperation with further institutes)
    • Bioassay and analysis
    • Microscopic investigations (REM, fluorescence microscopy)
    • Dissolution testing

     

    Processes

    • Freeze-drying
    • Spray-drying

     

    Bioactivity

    • in vitro screening
    • Cell lines (CaCo-2, MCF-7, BT-474, SKBR-3, TFK-1, EGI-1, HepG-2, HT-29, HEK-293)
    • Cytotoxicity
    • Cell proliferation
    • in vivo investigations in cooperation with the UKM (Muenster)
© Dziemba

Prof. Dr. Denise Steiner

Research group

Focus area of research:

  • Nanoparticulte systems
  • Lipid-based, nanoparticular carrier systems
  • Processing of drug nanoparticles
  • Innovative dosage forms
  • Orodispersible and mucoadhesive forms
  • 2D-printing of drug-containing inks

  • Analytics / Processes

    Analytics

    • Particle size measurements (laser diffraction, dynamic light scattering)
    • Differential scanning calorimetry
    • Microscopic examinations (SEM, fluorescence microscopy)
    • Mechanical properties such as tensile and compressive strength

     

    Processes

    • Spray drying
    • Fluidized bed granulation
    • Tableting
    • 2D-printing
    • Grinding (e.g. by dual centrifugation)
    • High-pressure homogenization